(NASDAQ: VERU) Veru's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.13%.
Veru's earnings in 2026 is -$13,608,554.On average, 5 Wall Street analysts forecast VERU's earnings for 2027 to be -$17,391,326, with the lowest VERU earnings forecast at -$19,549,897, and the highest VERU earnings forecast at -$12,531,985. On average, 5 Wall Street analysts forecast VERU's earnings for 2028 to be -$8,985,519, with the lowest VERU earnings forecast at -$11,529,426, and the highest VERU earnings forecast at -$6,982,106.
In 2029, VERU is forecast to generate -$13,826,104 in earnings, with the lowest earnings forecast at -$16,040,941 and the highest earnings forecast at -$11,278,787.